Top

Orphanet Journal of Rare Diseases

Published in:

Open Access 01-12-2022 | Research

Patient involvement in rare diseases research: a scoping review of the literature and mixed method evaluation of Norwegian researchers’ experiences and perceptions

Authors: Gry Velvin, Thale Hartman, Trine Bathen

Published in: Orphanet Journal of Rare Diseases | Issue 1/2022

Abstract

Background

Patients’ involvement (PI) in research is recognized as a valuable strategy for increasing the quality, developing more targeted research and to speed up more innovative research dissemination. Nevertheless, patient involvement in rare diseases research (PI-RDR) is scarce. The aims were: To study the Norwegian researchers` experiences and perceptions of PI-RDR and review the literature on PI-RDR.

Methods

1. A systematic scoping review of the literature on PI-RDR. 2. A cross-sectional questionnaire study with close-ended and open-ended questions to investigate the researchers` experiences.

Results

In the scoping review 608 articles read in full-text and 13 articles (one review and twelve primary studies) were included. The heterogeneity of the design, methodology and results was large. Most studies described several benefits of PI, but few described methods for measuring impacts and effectiveness of PI-RDR. In the cross sectional part of this study, 145 of 251 employees working in the nine Norwegian Centers on Rare Diseases participated, of these 69 were researchers. Most (95%) of the researchers claimed that rare diseases research is more challenging than for the more common diseases. The majority (95%) argued that PI-RDR may increase the quality of the studies and the relevance, and most (89%) agreed that PI-RDR in dissemination may increase the awareness and public interest for rare diseases. In the open-ended questions several researchers also claimed challenges related to PI-RDR, and many had proposal for improving PI and promotion of rare disease research.

Conclusion

Both the literature and researchers emphasized that PI-RDR is important for improving research quality and increase the public attention on rare diseases, but what constitutes effective PI-RDR still remain unclear. More research on the design, methodology and assessment for measuring the impact of PI-RDR is warranted.

Available only for authorised users

Nguengang WN, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73. https://doi.org/10.1038/s41431-019-0508-0.CrossRef

European Commission. Rare disorder definition 2019 (Available from: Rare diseases | Public Health (europa.eu).

Gagnon C, Fortin J, Lamontage ME, Plourde A. Methodological framework for the development of practive guidelines and knowledge tools for rare diseases. J Neuromuscul Dis. 2021. The rare knowledge mining methodological framework for the development of practice guidelines and knowledge translation tools for rare diseases - PubMed (nih.gov). https://doi.org/10.3233/JND-200536.

Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet Rare Dis. 2018;13(1):16. https://doi.org/10.1186/s13023-018-0810-x.CrossRef

Somanadhan S, Nicholson E, Dorris E, Brinkley A, Kennan A, Treacy E, et al. Rare Disease Research Partnership (RAinDRoP): a collaborative approach to identify research priorities for rare diseases in Ireland. HRB Open Res. 2020;3:13. https://doi.org/10.12688/hrbopenres.13017.2.CrossRefPubMedPubMedCentral

Cellucci T, Lee S, Webster F. Adapting knowledge translation strategies for rare rheumatic diseases. J Rheumatol. 2016;43(8):1462–8.CrossRef

Andersen T. The political empowerment of rare diseases patient advocated both at EU and national level. Orphanet J Rare Dis. 2012;7(2):A33. The political empowerment of rare disease patient advocates both at EU and national level (nih.gov).

Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, et al. A systematic review of approaches for engaging patients for research on rare diseases. J Gen Intern Med. 2014;29(3):788–800. https://doi.org/10.1007/s11606-014-2895-9.CrossRefPubMedCentral

Domecq JP, Prutsky G, Elaiyah T, Wang Z, Nabban M, Shippee N, et al. Patient engagement in research: a systematic review. GMC Health Serv Res. 2014;14(1):89. https://doi.org/10.1186/1472-6963-14-89.CrossRef

10.

INVOLVE: What is public involvement in research. UK: INVOLVE (NHS) (23.06.2020). Patient engagement in research resources—CIHR (cihr-irsc.gc.ca).

11.

Bariu C, Bonomi M, Borshchevsky I, Cools M, Craen M, Ghervan C, Hauschild M, Hershkovitz E. Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism. Orphanet J Rare Dis. 2017;12:57. https://doi.org/10.1186/s13023-017-0608-2.CrossRef

12.

Young K, Kaminstein D, Olivos A, Burroughs C, Castillo-Lee C, Kullman J, McAlear C, Shaw DG, Sreih A, Casey G, Vasculitis Patient-Powered Research Network, Merkel P. Patient involvement in medical research: what patients and physicians learn from each other. Orphanet J Rare Dis. 2019;2014:21. https://doi.org/10.1186/s13023-018-0969-1.CrossRef

13.

Hamakawa N, Kogetsu A, Isono M, Yamasaki C, Manabe S, Takeda T, et al. The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN project. Res Involv Engagem. 2021;7:9. https://doi.org/10.1186/s40900-021-00253-6.CrossRefPubMedPubMedCentral

14.

Dillon EC, Tuzzio L, Madrid S, Olden H, Greenlee RT. Measuring the impact of patient-engaged research: how a methods workshop identified critical outcomes of research engagement. J Patient Cent Res Rev. 2017;4(4):237–46. https://doi.org/10.17294/2330-0698.1458.CrossRefPubMedPubMedCentral

15.

Harriington R, Hanna ML, Oehrlein EM, Camp R, Wheeler R, Cooblall C, Tesoro T, Schott AM, et al. Defining patient engagement in research: results of a systemstic review and analysis: report of the ISPOR Patient-Centered Special Interest Group ScienceDirect. Value Health. 2020;23(6):677–88. https://doi.org/10.1016/j.jval.2020.01.019.CrossRef

16.

Crowe AL, McKnight J, McAneney. Communication needs for individual with rare diseases within and around the healthcare system of Northern Ireland. Front Public Health. 2019;7:236. Communication Needs for Individuals With Rare Diseases Within and Around the Healthcare System of Northern Ireland (nih.gov).

17.

Ayme S, Rodwell C. The European Union Committee of Experts on Rare Diseases: three productive years at the service of the rare disease community. Orphanet J Rare Dis. 2014. https://doi.org/10.1186/1750-1172-9-30.CrossRefPubMedPubMedCentral

18.

Syed AM, Camp R, Mischorr-Bach C, Houyez F, Aro AR. Policy recommendations for rare disease Centres of Expertise. Eval Program Plan. 2015;52:78–83. https://doi.org/10.1016/j.evalprogplan.2015.03.006.CrossRef

19.

Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidancen for authors when choosing between a systematic of scoping review approach. BMC Med Res Methodol. 2018;18:143. https://doi.org/10.1186/s12874-018-0611-x.CrossRefPubMedPubMedCentral

20.

Pham MT, Rajic A, Greig JD, Sargeant JM, Papadopoulos A, McEwen SA. A scoping review of scoping reviews: advancing the approach and enhancing the consistency. Res Synth Methods. 2014;5(4):371–85. https://doi.org/10.1002/jrsm.1123.CrossRefPubMedPubMedCentral

21.

Tricco AC, Lillie E, Zarin W, O’Brian KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):267–73. https://doi.org/10.7326/M18-0850.CrossRef

22.

Peters MD, Godfrey CM, Khalil H, Mc Inerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–6. https://doi.org/10.1097/XEB.0000000000000050.CrossRefPubMed

23.

Popay J, Roberts H, Sowden A, Petticrew M, Arai L. Guidance on the conduct of narrative synthesis in systematic reviews a product from the ESRC Methods Programme. 2006. Microsoft Word - NS synthesis guidance Version 1 April formatted 2006.doc (lancaster.ac.uk).

24.

National Resource Centre of Rare Diseases in Norway 2021 Senter for sjeldne diagnoser.

25.

The STROBE checklist STROBE-checklist-v4-combined.pdf and Checklists—STROBE (strobe-statement.org).

26.

Singer E, Couper MP. Some methodological uses of responses to open questions and other verbatim comments in quantitative surveys. Methods Data Anal. 2017;11(2):115–34. https://doi.org/10.12758/mda.2017.01.CrossRef

27.

Vitale DC, Armenakis AA, Field HS. Integrating qualitative and quantitative methods for organizational diagnoses. J Mixed Methods Res. 2008;2(1):87–105. https://doi.org/10.1177/1558689807309968.CrossRef

28.

Questback platforms: https://insightplatforms.com/platforms/questback/.

29.

Hotjar’s open-ended question analysis template, how to analyze open-ended questions in 5 steps [+Template Included] | Hotjar Blog.

30.

Guidelines for Research Ethics in the Social Sciences, Humanities, Law and Theology | Forskningsetikk 2021.

31.

Landy DC, Brinich MA, Colten ME, Horn EJ, Terry SF, Sharp RR. How disease advocacy organizations participate in clinical research: a survey of genetic organizations. Genet Med. 2012;14(2):223–8. https://doi.org/10.1038/GIM.0b013e3182310ba.CrossRefPubMed

32.

Ambrosini A, Quinlivan R, Meijer I, Schrijvers G, Padberg G, de Wit M, et al. “Be an ambassador for change that you would like to see”: a call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuro-muscular disease. Orphanet J Rare Dis. 2019;14(1):126. https://doi.org/10.1186/s13023-019-1103-8.CrossRefPubMedPubMedCentral

33.

Lochmuller H, Ambrosint A, van Engelen B, Hansson M, Tibben A, Breukelt A, Sterrenburd E, Schrijvers G, Meije I, Padbeg G, et al. The position of neuromuscular patients in shared decision making. Report from the 235th ENMC Workshop: Milan, Italy, January 19–20, 2018. J Neuromuscul Dis. 2019;6(1):161–72. https://doi.org/10.3233/JND-180368.CrossRefPubMed

34.

d’Udekem Y, Forsdick V, du Plessis K. Involvement of patients and parents in research undertaken by the Australian and New Zealand Fontan Registry. Cardiol Young. 2018;28:517–21. https://doi.org/10.1017/S1047951117001494.CrossRefPubMed

35.

Nunn JS, Gwynne K, Gray S, Lacaze P. Involving people affected by a rare condition in shaping future genomic research. Res Involv Engagem. 2021;7:14. https://doi.org/10.1186/s40900-021-00256-3.CrossRefPubMedPubMedCentral

36.

Roennow A, Sauve M, Welling J, Riggs RJ, Kennedy AT, Galetti I, Brown E, Leite C, Gonzales A, et al. Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations. BMJ Open. 2020. https://doi.org/10.1136/bmjopen-2020-039473.CrossRefPubMedPubMedCentral

37.

Swartz M, Zimmerman GM, Smith F, Sprecher E, Pachyonychia Congenita Project. A partnership of patient and medical professional. J Dermatol Nurses Assoc. 2013;5(1):42–7.CrossRef

38.

Merkel PA, Manion M, Gopal-Srivastava R, Groft S, Jinnah HA, Robertson D, Krischer JP, Rare Diseases Clinical Research Network. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis. 2016;11:66. https://doi.org/10.1186/s13023-016-0445-8.CrossRefPubMedPubMedCentral

39.

Pinto D, Martin D, Chenhall R. The involvement of patient organizations in rare disease research: a mixed methods study in Australia. Orphanet J Rare Dis. 2016;11:2. https://doi.org/10.1186/s13023-016-0382-6.CrossRefPubMedPubMedCentral

40.

Cossar J, Neil E. Service user involvement in social work research: learning from an Adoption Research Project. Br J Soc Work. 2015;45(1):225–40. https://doi.org/10.1093/bjsw/bct108.CrossRef

41.

Iliffe S, McGrath T, Mitchell D. The impact of patient and public involvement in the work of the Dementias & Neurodegenerative Diseases Research Network (DeNDRoN): case studies. Health Expect. 2013;16(4):351–61. https://doi.org/10.1111/j.1369-7625.2011.00728.x.CrossRefPubMed

42.

Vale CL, Thompson LC, Murphy C, Forcat S, Hanley B. Involvement of consumers in studies run by the Medical Research Council Clinical Trials Unit: results of a survey. Trials. 2012;13(13):9. https://doi.org/10.1186/1745-6215-13-9.CrossRefPubMedPubMedCentral

43.

Malterud K, Elvbakken KT. Patients’ participating ac co-researchers in health research: a systematic review of outcomes and experiences. Scand J Public Health. 2020;48(6):617–28. https://doi.org/10.1177/1403494819863514.CrossRefPubMed

44.

Bryson B, Bogart K, Atwood M, Fraser K, Locke T, Puch K, Zerrouk M. Navigating the unknown: a content analyses of the unique challenges faced by adults with rare diseases. J Health Psychol. 2021;25(5):623–35. https://doi.org/10.1177/1359105319828150.CrossRef

45.

Giggs RC, Batshaw M, Dunkle M, Gopai-Srivastava R, Kaye E, Krischer J, Nguyen T, et al. Clinical research for rare diseases: opportunities. Challenges Solut Med Genet Metab. 2009;96(1):20–6. https://doi.org/10.1016/j.ymgme.2008.10.003.CrossRef

46.

Gasterland CMW, Jansen-van der Weide MC, du Prie-Olthof MJ, Donk M, Kaatee MM, Kaczmarek R, Lavery C, Leeson-Beevers K, et al. The patients view on rare disease trial design—a qualitative study. Orphanet J Rare Dis. 2019;14:31. https://doi.org/10.1186/s13023-019-1002-z.CrossRef

47.

Hamiliton JG, Hutson SP, Frohnmayer AE, Han PKJ, Peters JA, Carr AG, Alter BP. Genetic information-seeking behaviors and knowledge among family members an patients with Inherited Bone Marrow Failure Syndromes. J Genet Couns. 2015;24(5):760–70. https://doi.org/10.1007/s10897-014-9807-3.CrossRef

48.

Hanisch M, Wiemann S, Bohner L, Jung S, Kleinheinz J. State of knowledge about information sources and health care centers for rare diseases among affected people in Germany. Cent Eur J Public Health. 2020;28(1):82–82. https://doi.org/10.21101/cejph.a5652.CrossRefPubMed

49.

Rare Barometer: Rare disease patients’ participation in research. A Rare Barometer survey EURORDIS - The Voice of Rare Disease Patients in Europe.

50.

SHORT GUIDE ON PATIENT PARTNERSHIPS IN RARE DISEASE RESEARCH PROJECTS. Europeuan Joint Program for Rare Diseases 2020 SHORT-GUIDE-ON-PATIENT-PARTNERSHIPS-IN-RARE-DISEASE-RESEARCH-PROJECTS.pdf (ejprarediseases.org).

51.

Staley K, Elliott J, Stewart D, Wilson R. Who should I involve in my research and why? Patients, carers or the public? Res Involv Engagem. 2021;7(1):41. https://doi.org/10.1186/s40900-021-00282-1.CrossRefPubMedPubMedCentral

52.

Mitani AA, Haneuse S. Small Data Challenges of Studying Rare Diseases. JAMA Netw Open. 2020;3(3): e201965. https://doi.org/10.1001/jamanetworkopen.2020.1965.CrossRefPubMed

53.

Gagne JJ, Thompson L, O’Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:6802. https://doi.org/10.1136/bmj.g6802.CrossRef

54.

Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. 2017;24(9):562–71. https://doi.org/10.1038/gt.2017.29.CrossRefPubMedPubMedCentral

55.

Hahn DL, Hoffmann AE, Felzien M, LeMaster JW, Xu J, Fagnan LJ. Tokenism in patient engagement. Fam Pract. 2017;34(3):290–5. https://doi.org/10.1093/fampra/cmw097.CrossRefPubMed

56.

Boaz A, Hanney S, Borst R, O’Shea A, Kok M. How to engage stakeholders in research design principles to support improvement. Health Res Policy Syst. 2018;2018(16):60. https://doi.org/10.1186/s12961-018-0337-6.CrossRef

Title: Patient involvement in rare diseases research: a scoping review of the literature and mixed method evaluation of Norwegian researchers’ experiences and perceptions
Authors: Gry Velvin
Thale Hartman
Trine Bathen
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2022
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-022-02357-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Patient involvement in rare diseases research: a scoping review of the literature and mixed method evaluation of Norwegian researchers’ experiences and perceptions

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Patients’ access to rare neuromuscular disease therapies varies across US private insurers

Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH)

Health insurance literacy and health services access barriers in Niemann–Pick disease: the patient and caregiver voice

Lived experiences of patients with distal renal tubular acidosis treated with ADV7103 and of their caregivers: a qualitative study

Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study

Molecular and clinical characterization of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED) in Iranian non-Jewish patients: report of two novel AIRE gene pathogenic variants